+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Biosimilar Monoclonal Antibodies Market Research Report by Drug Class (Abciximab, Adalimumab, and Bevacizumab), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 244 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4989642
UP TO OFF until Dec 31st 2022
The Global Biosimilar Monoclonal Antibodies Market size was estimated at USD 5,087.54 million in 2021, USD 6,253.40 million in 2022, and is projected to grow at a CAGR 23.09% to reach USD 17,697.35 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Biosimilar Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab.
  • Based on Application, the market was studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic is further studied across MAbs in Biochemical Analysis and MAbs in Diagnostic Imaging. The MAbs in Biochemical Analysis is further studied across Cancers, Hormonal disorders, Infectious diseases, and Pregnancy. The MAbs in Diagnostic Imaging is further studied across Atherosclerosis, Bacterial infections, Cancers, Cardiovascular diseases, and Deep vein thrombosis (DVT). The Therapeutic is further studied across MAbs as Direct Therapeutic Agents and MAbs as Targeting Agents in Therapy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biosimilar Monoclonal Antibodies market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilar Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilar Monoclonal Antibodies Market, including Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?
6. What is the market share of the leading vendors in the Global Biosimilar Monoclonal Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?
Frequently Asked Questions about the Global Biosimilar Monoclonal Antibodies Market

What is the estimated value of the Global Biosimilar Monoclonal Antibodies Market?

The Global Biosimilar Monoclonal Antibodies Market was estimated to be valued at $5087.54 Million in 2021.

What is the growth rate of the Global Biosimilar Monoclonal Antibodies Market?

The growth rate of the Global Biosimilar Monoclonal Antibodies Market is 23.0%, with an estimated value of $17697.35 Million by 2027.

What is the forecasted size of the Global Biosimilar Monoclonal Antibodies Market?

The Global Biosimilar Monoclonal Antibodies Market is estimated to be worth $17697.35 Million by 2027.

Who are the key companies in the Global Biosimilar Monoclonal Antibodies Market?

Key companies in the Global Biosimilar Monoclonal Antibodies Market include Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG and Reliance Life Sciences.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Focus on R&D to introduce innovative product pipeline
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facilitie
5.1.3.2. High adoption rate in developing countries
5.1.4. Challenges
5.1.4.1. Stringent regulations with the product approvals and cost structure associated with the manufacturing process
5.2. Cumulative Impact of COVID-19
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.2.1. MAbs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal disorders
7.2.1.3. Infectious diseases
7.2.1.4. Pregnancy
7.2.2. MAbs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular diseases
7.2.2.5. Deep vein thrombosis (DVT)
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MAbs as Direct Therapeutic Agents
7.4.2. MAbs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Allergan Plc
12.2. Biocon
12.3. BioXpress Therapeutics SA
12.4. Boehringer Ingelheim GmbH
12.5. Coherus BioSciences, Inc.
12.6. Genor BioPharma Co. Ltd
12.7. Intas Pharmaceuticals Limited
12.8. Novartis AG
12.9. Pfizer, Inc.
12.10. Reliance Life Sciences
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, 2019-2027 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, 2019-2027 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, 2019-2027 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2027
FIGURE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2019-2027 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2019-2027 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2019-2027 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, 2019-2027 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2019-2027 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, 2019-2027 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2019-2027 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, 2019-2027 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, 2019-2027 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2019-2027 (USD MILLION)
FIGURE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2019-2027 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), 2019-2027 (USD MILLION)
FIGURE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, 2019-2027 (USD MILLION)
FIGURE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2019-2027 (USD MILLION)
FIGURE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, 2019-2027 (USD MILLION)
FIGURE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, 2019-2027 (USD MILLION)
FIGURE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 58. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 60. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2027
FIGURE 62. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 68. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 69. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2027
FIGURE 70. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 72. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 73. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2027
FIGURE 74. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 75. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 76. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 77. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 78. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 79. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 80. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 81. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 82. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 83. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 84. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 85. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 86. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 87. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 88. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2027
FIGURE 89. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 90. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 91. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 92. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 93. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 94. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 95. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 96. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 97. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 98. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 99. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 100. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 101. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 102. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 22. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 24. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 27. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 29. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2019-2027 (USD MILLION)
TABLE 32. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 33. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 34. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2019-2027 (USD MILLION)
TABLE 38. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY STATE, 2019-2027 (USD MILLION)
TABLE 40. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 41. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 43. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 45. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2019-2027 (USD MILLION)
TABLE 48. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 50. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2019-2027 (USD MILLION)
TABLE 53. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 54. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 55. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2019-2027 (USD MILLION)
TABLE 58. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 59. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2019-2027 (USD MILLION)
TABLE 60. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2019-2027 (USD MILLION)
TABLE 63. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 64. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY STATE, 2019-2027 (USD MILLION)
TABLE 65. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2019-2027 (USD MILLION)
TABLE 68. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY STATE, 2019-2027 (USD MILLION)
TABLE 70. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 73. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 74. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 77. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2019-2027 (USD MILLION)
TABLE 78. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 79. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY STATE, 2019-2027 (USD MILLION)
TABLE 80. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 82. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2019-2027 (USD MILLION)
TABLE 83. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 85. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2019-2027 (USD MILLION)
TABLE 88. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 89. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY STATE, 2019-2027 (USD MILLION)
TABLE 90. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2019-2027 (USD MILLION)
TABLE 93. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 94. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY STATE, 2019-2027 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 97. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 98. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 99. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 100. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 102. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2019-2027 (USD MILLION)
TABLE 103. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 104. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY STATE, 2019-2027 (USD MILLION)
TABLE 105. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 107. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2019-2027 (USD MILLION)
TABLE 108. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 109. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 110. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 112. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 113. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 114. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 115. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 117. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 118. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 119. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 120. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 121. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 122. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 123. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 124. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 125. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 126. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 127. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 128. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 129. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 130. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 131. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 132. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 133. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 134. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 135. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 136. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 141. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 142. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 143. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 144. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 145. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 146. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 147. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 148. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 149. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 150. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 151. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 152. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 153. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 154. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 155. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 156. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 157. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 158. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 159. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 160. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 161. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 162. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 163. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 164. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 165. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 166. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 167. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 168. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 169. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 170. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 171. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 172. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 173. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 178. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 179. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 180. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 181. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 182. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 184. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 185. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 186. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 187. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 188. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 189. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 190. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 191. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 192. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 193. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 194. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 195. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 196. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 197. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 198. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 199. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 200. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 201. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 202. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 203. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 204. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 208. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 209. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 210. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 211. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 212. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 213. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 214. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RANKING
TABLE 215. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2021
TABLE 216. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET MERGER & ACQUISITION
TABLE 217. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 218. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 219. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET INVESTMENT & FUNDING
TABLE 220. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 221. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING

Companies Mentioned

  • Allergan Plc
  • Biocon
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co. Ltd
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences

Methodology

Loading
LOADING...